These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11751794)

  • 1. IMP-1 carbapenemase detected in an Acinetobacter clinical isolate from the UK.
    Tysall L; Stockdale MW; Chadwick PR; Palepou MF; Towner KJ; Livermore DM; Woodford N
    J Antimicrob Chemother; 2002 Jan; 49(1):217-8. PubMed ID: 11751794
    [No Abstract]   [Full Text] [Related]  

  • 2. Fortuitous diagnosis of NDM-1-producing Acinetobacter pittii carriage in a patient from France with no recent history of travel.
    Pailhoriès H; Hadjadj L; Mahieu R; Crochette N; Rolain JM; Kempf M
    J Antimicrob Chemother; 2017 Mar; 72(3):942-944. PubMed ID: 27999060
    [No Abstract]   [Full Text] [Related]  

  • 3. First report of OXA-23 carbapenemase in clinical isolates of Acinetobacter species in the Irish Republic.
    Boo TW; Walsh F; Crowley B
    J Antimicrob Chemother; 2006 Nov; 58(5):1101-2. PubMed ID: 16916867
    [No Abstract]   [Full Text] [Related]  

  • 4. [The high level resistance to carbapenems in Acinetobacter baumannii is a multifactorial problem].
    Bou G
    Enferm Infecc Microbiol Clin; 2001; 19(7):336-8. PubMed ID: 11747791
    [No Abstract]   [Full Text] [Related]  

  • 5. Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2.
    Brown S; Bantar C; Young HK; Amyes SG
    Lancet; 1998 Jan; 351(9097):186-7. PubMed ID: 9449879
    [No Abstract]   [Full Text] [Related]  

  • 6. Appearance of IMP-1 metallo-beta-lactamase in Europe.
    Cornaglia G; Riccio ML; Mazzariol A; Lauretti L; Fontana R; Rossolini GM
    Lancet; 1999 Mar; 353(9156):899-900. PubMed ID: 10093989
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergence of carbapenemase-producing Acinetobacter ursingii in The Netherlands.
    Sieswerda E; Schade RP; Bosch T; de Vries J; Chamuleau MED; Haarman EG; Schouls L; van Dijk K
    Clin Microbiol Infect; 2017 Oct; 23(10):779-781. PubMed ID: 28487169
    [No Abstract]   [Full Text] [Related]  

  • 8. bla(IMP) and bla(VIM) mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India.
    Amudhan MS; Sekar U; Kamalanathan A; Balaraman S
    J Infect Dev Ctries; 2012 Nov; 6(11):757-62. PubMed ID: 23277500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Report of the Carbapenemase Gene
    D'Souza R; Pinto NA; Higgins PG; Hwang I; Yong D; Choi J; Lee K; Chong Y
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of Acinetobacter pittii harboring New Delhi metallo-beta-lactamase genes in Daejeon, Korea.
    Sung JY; Koo SH; Kim S; Kwon GC
    Ann Lab Med; 2015 Sep; 35(5):531-4. PubMed ID: 26206691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending the reservoir of bla IMP-5: the emerging pathogen Acinetobacter bereziniae.
    Grosso F; Silva L; Sousa C; Ramos H; Quinteira S; Peixe L
    Future Microbiol; 2015; 10(10):1609-13. PubMed ID: 26439605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
    Wang H; Guo P; Sun H; Wang H; Yang Q; Chen M; Xu Y; Zhu Y
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4022-8. PubMed ID: 17846127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?
    Tamma PD; Wang R; Lewis S; Opene BNA; Simner PJ
    Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1378-1379. PubMed ID: 28965496
    [No Abstract]   [Full Text] [Related]  

  • 14. Production of a plasmid-encoded OXA-72 β-lactamase associated with resistance to carbapenems in a clinical isolate Acinetobacter junii.
    Fernández-Cuenca F; Rodríguez-Martínez JM; Gómez-Sánchez MA; de Alba PD; Infante-Martínez V; Pascual A
    Int J Antimicrob Agents; 2012 Jan; 39(1):93-4. PubMed ID: 21982835
    [No Abstract]   [Full Text] [Related]  

  • 15. First report of carbapenem-resistant Acinetobacter soli isolates coharboring blaNDM-1 and blaOXA-58 genes from China.
    Cao JG; Zhang H; Xu YP; Yan ZQ; Liu YX
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):407-8. PubMed ID: 26395155
    [No Abstract]   [Full Text] [Related]  

  • 16. IMP-1-producing carbapenem-resistant Acinetobacter ursingii from Japan.
    Endo S; Sasano M; Yano H; Inomata S; Ishibashi N; Aoyagi T; Hatta M; Gu Y; Yamada M; Tokuda K; Kitagawa M; Kunishima H; Hirakata Y; Kaku M
    J Antimicrob Chemother; 2012 Oct; 67(10):2533-4. PubMed ID: 22733654
    [No Abstract]   [Full Text] [Related]  

  • 17. First detection of an OXA-58 carbapenemase-producing Acinetobacter nosocomialis clinical isolate in the Balkan States.
    Strateva T; Sirakov I; Savov E; Mitov I
    J Glob Antimicrob Resist; 2018 Jun; 13():123-124. PubMed ID: 29665422
    [No Abstract]   [Full Text] [Related]  

  • 18. Common clinical substitutions enhance the carbapenemase activity of OXA-51-like class D β-lactamases from Acinetobacter spp.
    Mitchell JM; Leonard DA
    Antimicrob Agents Chemother; 2014 Nov; 58(11):7015-6. PubMed ID: 25155607
    [No Abstract]   [Full Text] [Related]  

  • 19. Emergence and dissemination of blaOXA-23-carrying imipenem-resistant Acinetobacter sp in a regional hospital in Taiwan.
    Lin MF; Kuo HY; Yeh HW; Yang CM; Sung CH; Tu CC; Huang ML; Liou ML
    J Microbiol Immunol Infect; 2011 Feb; 44(1):39-44. PubMed ID: 21531351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acinetobacter: a potential reservoir and dispenser for β-lactamases.
    Zhao WH; Hu ZQ
    Crit Rev Microbiol; 2012 Feb; 38(1):30-51. PubMed ID: 22007992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.